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Since the commercialization of the first therapeutic monoclonal antibody (mAb) product 
in 1986, this class of biopharmaceutical products have grown significantly. Due to the 
enhanced antigen binding and reduced cellular toxicity, they result in more efficacy in 
treatment of  variety of diseases. The global sales of mAbs which was 95.1 b$ in 2017 
have grown annually due to the dramatic increase in cancer and severe diseases rates and 
are estimated to reach 131.33 b$ by 2023, this represents a clear accelerating trend with 
more than 5.53% growth. In this review, we discuss some of these mAbs which have 
been approved by the FDA as well as others that are experiencing or being evaluated in 
clinical phases. Global sales of some monoclonal antibodies in 2016 are also considered, 
suggesting a significant increase in sales of mAbs over the years ahead.  
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Over the past 25 years, antibodies have become a major 
source of therapeutics for treatment of a wide spectrum 
of human diseases including cancers, infectious diseases, 
allergies, autoimmune diseases, and inflammations [1-3]. 
The ability of monoclonal antibodies (mAbs) to bind two 
antigens of the same type selectively with high affinity 
and elevated stability (in vitro and in vivo), signify them 
as suitable agents for therapeutic applications [4]. 
Compared to their polyclonal counterparts, mAbs are 
advantageous since they exhibit a much higher 
specificity and they are less susceptible to 
contaminations by pathogens [5, 6]. MAbs can also be 
conjugated to another therapeutic entities such as toxins 
or radioisotopes. The delivery of this entity to a target 
site can reduce potential side effects [7]. 
During the 1970s and 1980s, a series of technologies 
were developed which eventually converged to provide 
all of the technological and fundamental bases for the 
development of the therapeutic mAb industry. including 
the discovery of restriction enzymes [8], development of 
hybridoma technology [9] and site-directed mutagenesis 
[10-12]. In the 1980s, additional technologies and 
scientific discoveries were assisted to the development of 
recombinant antibodies such as phage display 
technology [13], Polymerase Chain Reaction (PCR) [14, 
15], sequencing and characterization of human germline 
antibody genes [16], and expression of antibody genes in 
cell cultures [17, 18]. Since the first therapeutic mAb 
was approved by Food and Drug Administration (FDA) 
in 1986 for clinical use in the treatment of organ 
transplant rejection [19, 20], extraordinary development 
has been seen in this field (Table 1). The global 
monoclonal antibodies market was 95.1 Billion USD in 
2017, nearly half of the biopharmaceutical market and it 
is estimated to reach 131.33 Billion USD by 2023 with a  
(Compound annual growth rate) CAGR of 5.53% during 
the period [18, 21] Figure 1 [22]. 
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2. Structural and functional features of antibodies 
Immunoglobulins (Igs) are exquisitely specific and 
naturally evolved molecules that recognize and eliminate 
foreign antigens. There are five classes of Igs: IgM, IgG, 
IgE, IgA, and IgD. From a biotechnology perspective, 
IgGs are the most important class of antibodies and exist 
both as soluble proteins and as membrane-bound 
receptors on the surface of B-lymphocytes. All of the 
immunoglobulins have a similar structure, consisting of 
two identical heavy chains (HCs) (MW~50 kDa) and 
two identical light chains (LCs) (MW~25 kDa). Each 
HC is attached to a LC via disulfide bonds, with 
additional disulfide bonds in the hinge region joining the 
two HCs together to complete the tetrameric structure 
(Figure 2). Both heavy and light chains of an 
immunoglobulin, are encoded by evolutionarily related 
members of a large multigene family. Functionally, each 
antibody can be consisted of two constant (Fc) region 
and an antigen-binding fragments (Fabs), which are 
connected via a flexible hinge region. The Fc portion of 
an antibody mediates effector functions, antibody-
dependent cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC). The human 
IgG1 is the most efficient structure in both CDC and 
ADCC, and therefore the most suitable for therapeutic 
applications against pathogens or tumor cells. 
3. Therapeutic antibody formats in clinical use 
3.1. Fully human mAbs 
Monoclonal antibodies are produced in different formats 
including Murine (100% mouse protein), Chimeric 
(approximately 65% human and 35% mouse protein), 
Humanized (95% human and 5% mouse protein) and 
Fully human (100% human protein) (Figure 3) [23]. 
Human anti-mouse antibody or Human anti-murine 
antibody (HAMA) is an antibody found in humans that 
responds to different protein sequences(Igs) which found 
in mice [24]. This immunologic reaction is against both 
variable and constant domains in chimeric antibody [25, 
26] Attaching the constant regions of a human antibody 
to the binding site domains of a murine antibody can’t 
solve the problem of immune responses. Antibody 
humanization method is a process which used to reduce 
the content of murine residues in the variable domains 
by adding of the six (complementary determining 
regions) CDR loops from murine variable domains to 
human variable frameworks [27].  
Lately, human mAbs are more developed than other 
chimeric or humanized antibodies. Although 
humanization process is often successful, it is difficult, 
time-consuming and superseded by the rapid, direct 
isolation of fully human antibodies from phage display 
libraries or transgenic mice. The first fully human mAb, 
Adalimumab, which developed via phage display 
technology, was approved in 2002 by the FDA and 
marketed under trade name Humira
®
 (Table 1). Two of 
transgenic mouse antibodies, panitumumab (manufactured 
by Amgen and marketed as Vectibix) and ustekinumab 
(manufactured by Janssen Biotech and marketed as 
Stelara), have now been approved for human therapeutic 
use, and over 160 additional similar antibodies are now 
in human clinical trials (Tabs, http://tabs.craic.com/, 
accessed May 2018). 
Although, mAbs have become an important therapeutic 
option, they often present severe drawbacks when they 
are using of full mAbs in patient’s therapy. So, 
researchers has determined recombinant antibody 
engineering techniques to develop new therapeutic mAb 
formats with the same activity as the whole size to 
escape these disadvantages [28]. New approaches, such 
as phage display [29, 30], are utilized to develop new 
therapeutically efficient antibody domains or fragments. 
Examples include Fab, single chain fragment variable 
(scFv), diabodies, domain antibodies (dAbs), bispecific 
antibodies, and intrabodies. These molecules suggest 
numerous therapeutic advantages, such as fast tissue 
penetration due to their small size and the capability to 
take on the exact tertiary structure [31]. 
3.2. The antigen binding fragments (Fabs) 
The Fab fragment antibody with a molecular weight of 
50 kDa, is monovalent, just containing a single antigen-
binding site. So far, Fabs are the most successful 
antibody fragments categories. they account for over 
49% of the fragments in active clinical development. 













nofetumomab merpentan] have been approved by FDA 
for clot prevention, Macular degeneration, severe Crohn 
disease and diagnosis of lung cancer, respectively. 
Currently, there are many companies developing 
different Fabs to treat various diseases (Table 2). As of 
the end of May 2018, there are 16 ongoing industry-
sponsored clinical trials and one of the trails is in phase 
III (Tabs, http://tabs.craic.com/, accessed May 2018). 
3.3. Single chain variable Fragments (scFvs) 
ScFv is a single chain monoclonal antibody, which has 
variable regions of light and heavy chains, jointed by 
flexible linker sequences, usually multiple glycines. In 
recent years, phage display of nonimmune, human naïve 
scFv antibody repertoires has proven to be an important 
tool for generating highly specific antibodies [8]. 
Blinatumomab is a CD19/CD3 bispecific antibody that is 
the first bispecific T-cell engager (BiTE) which 
approved by the U.S [32]. So far, about 65 scFvs are in 
clinical evaluation stage (Table 3) and two of them, 
Brolucizumab (anti-VEGF-A) and Pexelizumab (anti 
component 5) are in phase III clinical trials, although 
many more are still in preclinical development (Tabs, 
http://tabs.craic.com/, accessed May 2018). 
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) is a bispecific T-cell antibody 
against CD19. This antibody combines two binding sites, 
T-cell-specific CD3 and B-cell-specific CD19 which are 
brought in close proximity. Blinatumomab works by 
connecting these two cell types and activating the T-cell 
to apply cytotoxic activity on the target cell. Due to its 
short half-life, this antibody needs continuous 
intravenous infusion and thereforthe need for continuous 
exposure to the drug to exert sufficient efficacy, and 
lessenetoxicity. The drug was approved by FDA in 2014 
to the treatment of acute lymphoblastic leukemia (ALL). 
3.4. “Min¬iaturize” full-sized mAbs 
The new category of the antibody fragment is called the 
“Miniaturize” full-sized mAbs. Among the best 
examples of mAb, miniaturization are the small modular 
immunopharmaceuticals (SMIPs) from Trubion 
Pharmaceuticals. It only consists of one VL, one VH 
antigen binding domain and one constant “effectors” 
domain. The main difference between scFvs and SMIP is 
that the latter retains the immune effector function. So 
far, the SMIPs only account for 4% of the clinical 
pipeline.  
The most SMIPs advanced development project is TRU-
015, an anti-CD20 developed in collaboration with 
Wyeth, having progressed to Phase II for RA. Earlier 
attempts in systemic lupus erythematosus (SLE) and B 
cell lymphomas were ultimately discontinued. Trubion 
and Facet Biotechnology are collaborating in the 
development of phase II project Otlertuzumab (formerly 
known as TRU-016), which is a CD37-specific single-
chain, homodimeric therapeutic protein, for the treatment 
of CLL and other lymphoid neoplasias [33]. Wyeth has 
licensed the anti-CD20 SMIP SBI-087 for the treatment 
of autoimmune diseases, like as RA, SLE and possibly 
MS, although these projects remain in the earliest stages 
of clinical trials [34] (Table 4). 
3.5. Nanobodies 
Nanobodies are a novel class of recombinant antigen-
specific, single-domain, variable fragments of the 
naturally-occurring heavy chain only antibodies. Some 
preferred advantage of these fragments are minimal size, 
great stability, reversible refolding and prominent 
solubility in aqueous solutions and ability to exactly 
identify unique epitopes with subnanomolar affinity, 
have been combined to make them a valuable class of 
biomolecules for research and many medical diagnostic 
and therapeutic applications [35, 36] (Table 5). 
3.6. Antibody-drug conjugates 
Antibody-drug conjugates (ADCs) are becoming a 
progressively significant sub-class of antibody-related 
therapeutics. Two ADCs, brentuximab vedotin 
(Adcetris
®
) and adotrastuzumab emtansine (Kadcyla
®
), 
were recently approved for marketing both by the FDA 
and the EMA [37]. 
The approval accomplishments of these two ADCs 
might only be the first two of (potentially) many to 
come. As of the end of May 2018, there are more than 60 
novels ADCs currently being investigated in clinical 
trials for treatments of a variety of tumors. Nearly 70% 
of the 60 ADCs entered the clinical study in the past 
three years [38] (Table 6). 
3.7. Antibody-Radionuclide Conjugates 
This approach based on the use of monoclonal antibodies 
as delivery carriers for radionuclides, such as 
Tositumomab- I
131
and Ibritumomabtiuxetan, leading to 
obtain better imaging and therapy of cancer, which 
demonstrates the unique theranostic (therapy+diagnostic) 
potential of radioimmunoconjugates. At first, a cancer 
patient would receive a diagnostic dose of a radio 
immuno conjugates compatible with imaging procedures. 
If acceptable antibody localization of disease is 
achieved, the therapeutic dose of the same antibody 
labeled with a radio nuclide capable of inducing curative 
effects will be injected [39, 40] (Table 7). 
3.8. Immunotoxins 
Immunotoxins (ITs) such as Gemtuzumab ozogamicins 
are chimeric proteins consist of an antibody linked to a 
toxin [41]. The antibody confers specificity, whereas the 
toxin confers cytotoxicity. ITs have been used in both 
mice and humans to eliminate tumor cells, autoimmune 
diseases, and virus-infected cells [42, 43]. 
3.9. Antibody-Radionuclide Conjugates 
Immunostimulatory mAbs is defined as mediators that 
increase ongoing immune reactions. Utilizing mAbs to 
stimulate the immune response against tumor cells is a 
novel indirect mode of action, achieved by either 
blocking inhibitory ‘immune checkpoint’ receptors such 
as Cytotoxic T-Lymphocyte-Associated Protein 4 
(CTLA-4), or triggering activating receptors such as 4-
1BB or CD40 [44]. Some of these antibodies such as 
ipilimumab and tremelimumab have already entered 
clinical trials [45, 46]. 
4. Novel technologies in production of fully 
human mAbs 
4.1. Transgenic Mice 
In 1985, the possibility of generation of transgenic mice 
producing human antibodies (humanized mice) was 
suggested. Transgenic mice in which the native 
immunoglobulin repertoire has been replaced with 
human V-genes in the murine chromosome have been 
generated [47-49]. The desired antigen can be injected to 
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the transgenic mice, and the resulting antibody genes are 
recovered by selection technologies [50]. Vectibix
® 
was 
the first fully human antibody developed using Abgenix 
Xeno Mouse
TM
 technology and marketed in 2006 [51]. 
4.2. Phage display technology 
Phage display involves the introduction of foreign 
peptide sequences into the genome of the phage leading 
to presentation and "display" of large peptide libraries on 
the surface of phage as a fusion product to coat proteins. 
These statues provide means for selection of proteins and 
antibodies with specific binding ability against almost 
any target. This technology was initially introduced by 
George Smith in 1985 [13]. The starting point is usually 
an antibody library which comprises a population of 
clones. The bacteriophages are the main vehicle for 
presenting large peptides and protein libraries on their 
surface which are normally screened through biopanning 
process within a couple of weeks [13]. After usually 
three rounds of selection, the population is enriched for a 
high percentage of antibody fragments specific for the 
target antigen. The main benefit of phage display is a 
physical linkage between phenotype and genotype. This 
implies that selection of bacteriophage harboring a fused 
single binding molecule to phage coat proteins, enables 
us to isolate and identify its cognate genome by 
sequencing the encoding genome after amplification [30, 
52]. Currently, more than 60 phage display derived 
antibody and peptides are in late-stage clinical trials or 
approved [53] (Table 8). 
5. Conclusion 
Antibody based drugs proved to play an important role 
in the treatment of numerous human diseases over the 
past three decades. A large number of engineered 
antibodies in clinical development demonstrate the value 
of this type of therapeutic antibodies. With the use of 
advanced and novel technologies like phage display for 
mAb production, their dominance as the major class of 
biopharmaceutical products will continue. 
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Autoimmune diseases (ankylosing 
spondylitis, juvenile RA, psoriasis, 
psoriatic arthritis, RA) 
Enbrel Etanercept 1998 
Remicade Infliximab 1998 




Rituxan Rituximab CD20 1997 NHL 
Herceptin Trastuzumab HER2 1998 Breast cancer 
Avastin Bevacizumab VEGF 2004 Colorectal cancer 
Erbitux Cetuximab EGFR 2004 Colorectal cancer 
Keytruda Pembrolizumab PD-1 2014 Melanoma 
Yervoy Ipilimumab CTLA-4 2011 Melanoma 
Opdivo Nivolumab PD-1 2014 Melanoma 
Ibrance Palbociclib CDK-4,CDK5 2017 
Breast cancer 
(HRpositive,HER2negetive) 
Imbruvica Ibrutinib BTK 2013 
Chronic lymphocytic leukemia, Mantle 
cell lymphoma 
Perjeta Pertuzumab HER2 2012 Breast Cancer 
Xolair Omalizumab IgE 2003 Asthma 
Orencia Abatacept CD80/CD86 2005 RA 
Soliris Ecolizumab Com. C5 2007 PNH 
Stelara Ustekinumab IL-12/IL-23 2013 Psoriatic arthritis 
Tysabri Natalizumab alpha-4 integrin 2006 MS 
Ophthalmic 6.58 
Lucentis Ranibizumab VEGF 2006 Wet AMD 
Eylea Aflibercept VEGF 2011 Wet AMD 
Antiviral 1.40 Synagis Palivizumab RSV 1998 RSV 
Abbreviations: RA, rheumatoid arthritis; RSV, respiratory syncytial virus; NHL, non-Hodgkin’s lymphoma; TNF, tumor necrosis factor; PNH, paroxysmal 
nocturnal hemoglobinuria; AMD, age-related macular degeneration; HR, Hormone Receptor. (pharmalive, http//::pharmalive.com/ accessed June 2018), (pmlive, 







Figure 1.  Comparison of marketed mAbs sales in 2016. 
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Figure2. Structures of a full-size antibody and antibody fragments. Nomenclature and structural features of antibody 
fragments Fc, Fab, F(ab′)2, and scFv compared to a full size immunoglobulin (IgG). Recombinant antibodies (rAbs) are 




Figure 3. Antibody engineering for humanization. 
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Table 2. Therapeutic Fab fragments 
Phase Name Antigen Company Number of clinical trials 
Approved 
Ranibizumab VEGF-A Genentech, Novartis 302 
Certolizumab Pegol TNF-alpha Astellas, Celltech, Dermira, UCB, Xoma 90 
Abciximab Integrin αIIbβ3 Centocor Ortho, Isu Abxis, Lilly 62 
Nofetumomab Merpentan EpCAM Boehringer, NeoRx  
Phase III 
Onartuzumab cMet Genentech 9 
Lampalizumab Complement Factor D Genentech 7 
Phase II 
Dapirolizumab Pegol CD40L Biogen, UCB 3 
Alacizumab Pegol VEGFR-2 UCB 1 
Phase I Citatuzumab Bogatox EpCAM Univ. Zurich, Viventia 1 
(Tabs, http://tabs.craic.com/, accessed May 2018). 
 
Table 3. Therapeutic scFv fragments 
Phase Name Antigen Company Number of clinical trial 
Approved Blinatumomab CD-19, CD-3 Amgen, Medimmun, MicrometAG 38 
Phase III 
Brolucizumab VEGF-A Delenex, ESBATech, Novartis 7 
Pexelizumab C5 Alexion 3 
Phase II 
Moxetumomab Pasudotox CD22 Medimmune 15 
Vobarilizumab IL-6R Abbvie, Ablynx 6 
Esba 1622 TNFα ESBATech 2 
Sloan-Kettering Patent Anti-B7H3 B7-H3 Sloan-Kettering 3 
Oportuzumab Monatox EpCAM Viventia 3 
Phase I/II 
Efungumab HSP90 NeuTec, Novartis 3 
Radretumab Fibronectin Bayer, Philogen 1 
Phase I 
Cirmtuzumab ROR 1 U.California 3 
Duke D2C7 EGFR Duke U. 1 
(Tabs, http://tabs.craic.com/, accessed May 2018) 
 
Table 4. Therapeutic SMIPs  
Phase Name Antigen Company Number of clinical trials 
Phase II 
SBI-087 CD-20 Pfizre, Trubion 4 
Otlertuzumab CD-37 Aptevo, Emergent, Facet, Trubion 4 
 
Table 5. Therapeutic nanobodies 
Phase Name Antigen Company Number of clinical trials 
Phase III Caplacizumab vWF Ablynx 4 
Phase II 
ALX-0761 IL-17, IL-17F Ablynx, Merck Serono 2 
ALX-0681 vWF Ablynx 1 
Phase I 
ALX-0171 RSV Ablynx 3 
PF-05230905 TNF-alpha Ablynx, Pfizer 1 
ALX-0651 CXCR4 Ablynx 1 
TAS266 DR5 Ablynx, Novartis 1 
KN035 PD-1 Alphamab 1 
ALX-0141 RANKL Ablynx, Eddingpharm  
BI 1034020 Amyloid beta Ablynx, Boehringer  
(Tabs, http://tabs.craic.com/, accessed May 2018). 
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Table 6. Therapeutic ADCs 
Phase Name Antigen Company Number of clinical trial 
Approved 
Brentuximab Vedotin CD-30 Millennium, seattle Genetics 113 
Gemutuzumab Ozogamicin CD-33 PDL, Pfizer, wyeth 55 
Inotuzumab Ozogamicin CD-22 Pfizer, UCB, wyeth 28 
Trastuzumab Emtansine HER2/neu Genentech, Immunogen, PDL, Roche 27 
Phase III 
Trastuzumab Deruxtucan HER2/neu Daiichi Sankyo 9 
Mirvetuximab Soravtansine FRA ImmunoGen 6 
Enfortumab Vedotin Nectin-4 Agensys, Astellas, Seattle Genetics 6 
Vadastuximab Talirine CD-33 Seattle Genetics 5 
Depatuxizumab Mafodotin EGFR Abbvie, seattle Genetics 5 
Syd985 HER2/neu Synthon 2 
(Tabs, http://tabs.craic.com/, accessed May 2018). 
 
Table 7. Therapeutic radiolabeled antibodies 
phase Name Antigen Company Number of clinical trial 
Approved 
Ibritumomab tiuxetan CD-20 Biogen, CTI Biopharma, spectrum 81 
Tositumomab CD-20 GSK 28 
Capromab pendetide PSMA Cytogen, EUSA 2 
Votumumab CTAA16.88 Organon Technika  
Phase III Clivatuzumumab tetraxetan MUC1 Immunomedics 5 
(Tabs, http://tabs.craic.com/, accessed May 2018). 
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Table 8. Therapeutic Phage display derived antibodies 


























Belimumab (Benlysta®) BAFF GSK, HGS Approved (2011) 








Gevokizumab IL-1β XOMA 
Beriakinumab IL-12 Abbott, CAT 
Tralokinumab IL-13 AstraZeneca, Medimmune 

















Seribantumab HER3 Sanofi ,Merrimack 
Anetumab Ravtansine Mesothelin Bayer, Immunogen, Morphosys 
Fresolimumab TGF-β CAT, Genzyme 
Mapatumumab TRAIL-R1 HGS 
Guselkumab IL-23 Centocor Ortho, Morphosys 
Drozitumab DR5 Genentech 
Namilumab GM-CSF Micromet, Nycomed, Takeda 
Duligotuzumab EGFR, HER3 Genentech, Roche 
Carlumab MCP-1 Centocor Ortho, J&J, Morphosys 
Mavrilimumab GM-CSF2RA CAT, CSL, Medimmune 
BIIb033 LINGO-1 Biogen Idec 
BHQ880 DKK-1 Morphosys, Novartis 
BI-505 ICAM-1 BioInvent 
Orticumab oxLDL BioInvent, Genentech 
NI-0801 IP-10 NovImmune 
Adecatumumab EpCAM Merck Serono, Micromet 
 
 
 
